Generation Bio - GBIO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.50
  • Forecasted Upside: 202.42%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.48
▲ +0.1 (4.20%)

This chart shows the closing price for GBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Generation Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GBIO

Analyst Price Target is $7.50
▲ +202.42% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Generation Bio in the last 3 months. The average price target is $7.50, with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 202.42% upside from the last price of $2.48.

This chart shows the closing price for GBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Generation Bio. This rating has held steady since October 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/13/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/12/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/10/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/8/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/7/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/6/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/4/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/8/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
8/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00
5/14/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00
3/7/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00
3/7/2024Needham & Company LLCLower TargetBuy ➝ Buy$14.00 ➝ $10.00
11/10/2023WedbushLower TargetOutperform ➝ Outperform$11.00 ➝ $9.00
11/10/2023William BlairReiterated RatingMarket Perform
11/2/2023William BlairReiterated RatingMarket Perform
10/23/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Perform
10/19/2023TD CowenDowngradeOutperform ➝ Market Perform
10/18/2023WedbushReiterated RatingOutperform$11.00
8/16/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$8.00 ➝ $9.00
8/3/2023Needham & Company LLCReiterated RatingBuy$14.00
8/3/2023WedbushReiterated RatingOutperform ➝ Outperform$11.00
4/19/2023Needham & Company LLCReiterated RatingBuy$14.00
3/23/2023Needham & Company LLCReiterated RatingBuy$14.00
3/22/2023William BlairReiterated RatingMarket Perform
3/6/2023JMP SecuritiesLower TargetMarket Outperform$7.00 ➝ $2.23
2/24/2023Needham & Company LLCLower TargetBuy$23.00 ➝ $14.00
1/19/2023JMP SecuritiesLower TargetMarket Outperform$11.00 ➝ $7.00
11/8/2022Canaccord Genuity GroupInitiated CoverageBuy$9.00
11/7/2022Canaccord Genuity GroupInitiated CoverageBuy
8/8/2022JMP SecuritiesBoost TargetMarket Outperform$10.00 ➝ $11.00
8/5/2022WedbushReiterated RatingOutperform$24.00
8/5/2022Needham & Company LLCLower TargetBuy$27.00 ➝ $23.00
4/12/2022Needham & Company LLCReiterated RatingBuy$27.00
12/15/2021Needham & Company LLCLower TargetBuy$50.00 ➝ $27.00
12/15/2021JMP SecuritiesLower TargetMarket Outperform$40.00 ➝ $10.00
12/15/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
12/14/2021William BlairDowngradeOutperform ➝ Market Perform
6/8/2021JMP SecuritiesInitiated CoverageOutperform$40.00
3/22/2021JPMorgan Chase & Co.Boost TargetOverweight$34.00 ➝ $39.00
2/23/2021William BlairInitiated CoverageOutperform$45.00
2/18/2021Needham & Company LLCInitiated CoverageBuy$50.00
7/7/2020JPMorgan Chase & Co.Initiated CoverageOverweight$28.00
7/7/2020WedbushInitiated CoverageOutperform$31.00
7/7/2020CowenInitiated CoverageOutperform
7/7/2020Jefferies Financial GroupInitiated CoverageBuy$38.00
(Data available from 10/4/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/8/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/7/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/6/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2024
  • 9 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/5/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/4/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/4/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Generation Bio logo
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $2.48
Low: $2.37
High: $2.51

50 Day Range

MA: $2.59
Low: $2.17
High: $3.51

52 Week Range

Now: $2.48
Low: $0.86
High: $4.65

Volume

86,812 shs

Average Volume

190,756 shs

Market Capitalization

$164.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Generation Bio?

The following equities research analysts have issued reports on Generation Bio in the last twelve months: JMP Securities, Needham & Company LLC, TD Cowen, Wedbush, and William Blair.
View the latest analyst ratings for GBIO.

What is the current price target for Generation Bio?

2 Wall Street analysts have set twelve-month price targets for Generation Bio in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 215.1%. Needham & Company LLC has the highest price target set, predicting GBIO will reach $10.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $5.00 for Generation Bio in the next year.
View the latest price targets for GBIO.

What is the current consensus analyst rating for Generation Bio?

Generation Bio currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GBIO, but not buy more shares or sell existing shares.
View the latest ratings for GBIO.

What other companies compete with Generation Bio?

How do I contact Generation Bio's investor relations team?

Generation Bio's physical mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company's listed phone number is 617-655-7500 and its investor relations email address is [email protected]. The official website for Generation Bio is generationbio.com. Learn More about contacing Generation Bio investor relations.